TD Asset Management
RLMD icon

TD Asset Management’s Relmada Therapeutics RLMD Stock Holding History

TD Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,000
Closed -$75K – 1434
2023
Q3 		$75K Buy
25,000
+12,500
+100% +$37.1K ﹤0.01% 1388
2023
Q2 		$30.8K Hold
12,500
– – ﹤0.01% 1396
2023
Q1 		$28.3K Hold
12,500
– – ﹤0.01% 1412
2022
Q4 		$43.6K Hold
12,500
– – ﹤0.01% 1421
2022
Q3 		$452K Buy
12,500
+500
+4% +$13.9K ﹤0.01% 1314
2022
Q2 		$228K Buy
12,000
+3,545
+42% +$77.3K ﹤0.01% 1374
2022
Q1 		$228K Buy
+8,455
New +$175K ﹤0.01% 1416
2020
Q1 		– Sell
-6,493
Closed -$253K – 1424
2019
Q4 		$253K Buy
+6,493
New +$197K ﹤0.01% 1340

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TD Asset Management's RLMD Position: Q4 2023 in Review

TD Asset Management sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 25,000 shares — an estimated $75K sold.

TD Asset Management first reported a position in RLMD in Q4 2019 and held it in 8 quarters. The position peaked at $452K in Q3 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • TD Asset Management reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • TD Asset Management sold 25,000 Relmada Therapeutics shares in Q4 2023, an estimated $75K.
  • TD Asset Management first reported a position in Relmada Therapeutics in Q4 2019 and held it in 8 quarters.
  • TD Asset Management's Relmada Therapeutics position peaked at $452K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on TD Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.